Combinations of cannabinoids, vitamins, trace elements, bioactive components, bioflavonoid polyphenols, proteolytic enzymes, amino acids, and antioxidants which work independently and synergistically for the prevention, treatment, and inhibition of excess cytokines caused by the immune response to extreme viral and bacterial infections, including the inhibition of COVID-19, Rhinovirus and/or other virus spike proteins and mRNA vaccine spike proteins from attaching to body organ cells, penetrating cell membranes, and the replication of virus particles and spike proteins inside the cells. Inhibition of inflammation and prevention of long-term side effects, health issues (long-haulers), and disease caused by the SARS-CoV-2 and its variants, Rhinovirus, other viruses, bacteria, and mRNA vaccines are provided by the nutraceutical compositions. Specific combinations of these compounds work synergistically to increase the efficacy of the independent nutraceuticals in treatment.

The invention relates to a human milk oligosaccharide (HMO) for use in supplementing the diet of a pregnant woman, a synthetic composition comprising an HMO for use in supplementing the diet of a pregnant woman, and a method for improving health outcomes in an infant by supplementing the diet of a pregnant woman.

An antithrombotic composition containing an extract of Vespa velutina nigrithorax as an active ingredient, and more particularly, a pharmaceutical composition and a health functional food for preventing, ameliorating or treating thrombosis by inhibition of blood coagulation and inhibition of platelet aggregation, which contain an ethyl acetate fraction of an extract of Vespa velutina nigrithorax as an active ingredient. The extract exhibits antithrombotic activity by inhibiting platelet aggregation while exhibiting strong anticoagulant activity by inhibiting thrombosis-related enzymes and blood clotting factors. Also, the extract has no human erythrocyte hemolytic activity, has excellent heat stability, and the thrombosis-related enzyme and blood clotting factor inhibitory effects thereof are not lost even under an acidic condition of pH 2 and in plasma.

The invention concerns a process for the treatment of a sweet whey material containing cGMP (caseinoGlycoMacroPeptide), said process comprising the following steps: —Decationising the sweet whey material so as to obtain sweet whey material having a pH value of 1 to 4.5; —Treating said sweet whey in a fluidized bed reactor comprising a specific volume of an anionic resin, at a temperature between 10 and 18° C., wherein said sweet whey contacts said resin for a sufficient amount of time so that the resin absorbs between 52% and 58% of the cGMP present in the sweet whey; and—Recovering a protein material. Advantageously, the protein material is suitable for hypoallergenic infant formulae.

The invention relates to an expanded dry food product comprising at least the following ingredients: a food-grade plant- or animal-based protein concentrate; a food-grade fat; a food-grade texturising additive selected from the group consisting of plant-based hydrocolloids and gelling agents, starch, preferably modified starch, proteolytic additives and hydrolysis products thereof, and acidifying agents and salts thereof; and residual water. The invention also relates to a method for producing said expanded dry food product from a thermally expandable precursor.

A supplement includes plant-derived phosphatidylserine in a physiologically beneficial amount and at least one plant-based concentrate or extract which promotes a melatonergic benefit.

The present invention provides a composition comprising: honey; bee pollen; royal jelly; and propolis, wherein the content of the honey is 70% by mass or more and less than 100% by mass relative to the whole amount of the composition; the content of the bee pollen is more than 0% by mass and 10% by mass or less in terms of solid content relative to the whole amount of the composition; the content of the royal jelly is more than 0% by mass and 10% by mass or less in terms of solid content relative to the whole amount of the composition; and the content of the propolis is more than 0% by mass and 10% by mass or less in terms of solid content relative to the whole amount of the composition.

The present invention relates to methods of co-administration of various vitamins and mineral compositions, and in a specific embodiment, said methods comprise co-administering one composition comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D.sub.3, vitamin E, iron, magnesium and zinc, and a second composition comprising omega-3 fatty acids such as DHA, to supplement the nutritional needs of individuals within physiologically stressful states; and kits provided for co-administration of various vitamin and mineral compositions, and in a specific embodiment, said kits comprise one composition comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D.sub.3, vitamin E, iron, magnesium and zinc, and a second composition comprising omega-3 fatty acids, such as DHA, to supplement the nutritional needs of individuals within physiologically stressful states.

Disclosed are nutritional compositions including human milk oligosaccharides and nucleotides that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.

A composition for reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes a Nrf2 transcription factors that promotes transcription of antioxidant genes.